• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » UPDATE: Boston Scientific jumps on Watchman approval

UPDATE: Boston Scientific jumps on Watchman approval

March 16, 2015 By Brad Perriello

UPDATE: Boston Scientific jumps on Watchman approval

Investors sent shares of Boston Scientific (NYSE:BSX) up nearly 4% today after the medical device company said the FDA approved its long-delayed Watchman anti-stroke device.

BSX shares were trading at $17.20 apiece in mid-day activity today, up 3.6%, as investors reacted to the decade-long odyssey Boston Scientific undertook in getting Watchman on the U.S. market.

Pre-market approval from the FDA came only after an unprecedented 3 advisory panel meetings to evaluate Watchman, which is designed to lower the risk of stroke by closing off the heart’s left atrial appendage. One analyst today said the approval is good news not only for Boston Scientific but also rival St. Jude Medical (NYSE:STJ) and its Amplatzer cardiac plug.

"We view the Watchman label, which is relatively ‘broad’ versus what some investors feared, as a key positive not only for BSX, but also for STJ, who can now design a trial to randomize against Watchman (vs. an event-driven trial) and get approval for a reasonably large estimated population," Barclays analyst Matthew Taylor wrote.

"BSX continues to view LAA as a $500 MM market (~10 MM patient with AF; ~50% with an elevated risk for stroke; ~30% eligible but not well controlled or able to take warfarin; ~5% annual penetration rate; resulting in ~75 K procedures). BSX continues to believe that Watchman is a good option for patients to get off their pharma regimen and reduce stroke risk and live a more normal lifestyle," Taylor wrote. "For reference, this is actually how STJ defined the market at its 2013 analyst day, but BSX has made similar cuts at the market to come up with its estimate."

Leerink Partners analyst Danielle Antalffy agreed that the FDA’s indication is "relatively broad" but that adoption will be gated by reimbursement.

"Watchman was approved with a relatively broad label, with the FDA essentially leaving it to the physician and patient to decide whether the device is appropriate," Antalffy wrote. "While the FDA label is relatively broad, CMS could limit adoption by restricting reimbursement. Assuming, however, that CMS reimburses per the FDA-labeled indication, Watchman could ultimately address a significantly larger patient population than the ~50,000 cited by BSX."

Sterne Agee’s Gregory Chodaczek disagreed on the label, calling it "slightly restrictive," but concurred that reimbursement is a gating factor.

"While we think Watchman could eventually reach $500 million in sales, we continue to believe the timeline is longer than that of the company’s due to the lack of reimbursement, the lack of long-term data, a slightly restrictive label and a slow, methodical U.S . rollout," Chodaczek wrote.

Filed Under: Cardiac Implants, News Well, Pre-Market Approval (PMA), Regulatory/Compliance, Wall Street Beat Tagged With: Boston Scientific, Stroke

More recent news

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • Ancora Heart reaches enrollment milestone in pivotal heart failure device trial
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Johnson & Johnson launches daily disposable multifocal toric contact lens
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy